GemPharmatech (688046.SH) shareholder Qingdao National Pharmaceutical reduced its holdings by 888,200 shares, decreasing its stake to 5%.
Yaokang Biopharmaceuticals (688046.SH) announced that on September 24, 2024, the company's shareholder, Qingdao Guoyao Daichuang...
GemPharmatech (688046.SH) announced on September 24, 2024, that its shareholder Qingdao Guoyao DaChuang Investment Partnership Enterprise (Limited Partnership) (referred to as "Qingdao Guoyao") has reduced its shareholding in the company by 888,200 shares through block trading, accounting for 0.22% of the total share capital of the company. After this equity change, Qingdao Guoyao holds a reduced stake of 5% in the company.
Related Articles
GUOTAI JUNAN I: Why are gold and US Treasury bonds rising together amid the frenzy of "depreciation trading" in the US dollar?
SINO BIOPHARM (01177): The study data of the first-line treatment of advanced stage III breast cancer with the combination of Comorsi and Fluvisq was announced at ESMO 2025.
HK Bull/Bear Outstanding Qty Ratio(59:41) | October 21st
GUOTAI JUNAN I: Why are gold and US Treasury bonds rising together amid the frenzy of "depreciation trading" in the US dollar?
SINO BIOPHARM (01177): The study data of the first-line treatment of advanced stage III breast cancer with the combination of Comorsi and Fluvisq was announced at ESMO 2025.
HK Bull/Bear Outstanding Qty Ratio(59:41) | October 21st
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
